American Pharmacy News Reports Stories

Anthony Maddaluna began working at Pfizer in 1975.

Pfizer's executive vice president and president of global supply Anthony Maddaluna is retiring after 41 years with the company. Read More »

Onxeo receives DSMB recommendation for Phase III Livatag study

This is the ninth unanimous recommendation Onxeo has received from the DSMB.

The Data Safety Monitoring Board has awarded Onxeo S.A. with its ninth unanimous recommendation. Read More »

Agios releases first AG-120 dose expansion cohort data

The trial evaluated AG-120's safety and tolerability.

Agios Pharmaceuticals recently presented the first data from its Phase 1 AG-120 study dose expansion cohorts at the Society for Neuro-Oncology annual meeting. Read More »

AMCP holds national health care forum on oncology

The Academy of Managed Care Pharmacy (AMCP) recently hosted a national health care forum about value and outcomes in oncology where the key topics of conversation revolved around the fast-growing innovations in oncology and how complex cancer treatments h

The Academy of Managed Care Pharmacy recently hosted a national health care forum about value and outcomes in oncology where the key topics of conversation revolved around the fast-growing innovations in oncology and how complex cancer treatments have become. Read More »

Novocure long-term EF-14 trial data consistent with interim report

The data analyzed at the end of the trial was consistent with interim data.

Novocure's long-term data results of its Phase 3 EF-14 trial involving Optune combined with temozolomide are consistent with the results from the interim analysis of the data. Read More »

Celgene acquires Triphase’s MRZ

American Pharmacy News Reports | Nov 22, 2016

$Marizomib is being developed for the treatment of glioblastoma and relapsed and/or refractory multiple myeloma.$

Celgene Corp. has purchased Triphase Accelerator Corp.'s assets regarding its proteasome inhibitor, marizomib, which is being developed for the treatment of glioblastoma and relapsed and/or refractory multiple myeloma. Read More »

Boston Globe names Merck KGaA one of “Top Places to Work”

American Pharmacy News Reports | Nov 22, 2016

Merck KGaA was also No. 11 on a list of top 20 employers in the global biopharmaceutical industry.

Merck KGaA's businesses in Massachusetts have been ranked among the “Top Places to Work” by The Boston Globe. Read More »

Bayer to proceed with Phase 3 Nifurtimox trial

Bayer unveiled the study at the American Society of Tropical Medicine and Hygiene's annual meeting.

Bayer has formed a Phase 3 clinical trial that will assess the safety and effectiveness of Nifurtimox, a formulation designed to treat children of all ages that have been diagnosed with Chagas disease. Read More »

CSL Behring reports positive AEGIS-I trial results

CSL Behring's Phase 2b clinical trial involving AEGIS-I has turned in positive results. Read More »

RepathaA can lead to decrease of atherosclerosis in CAD patients

The results of the trial were published in the Journal of the American Medical Association.

Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »

Akcea generates positive IONIS-ANGPTL3-LRx trial results

The potential of ANGPTL3 reduction to improve cardiovascular risk is also supported by genetic studies in humans.

Akcea Therapeutics' Phase 1/2 trial involving IONIS-ANGPTL3-LRx has turned in positive results. Read More »

Phase 1 inclisiran trial results published in New England Journal of Medicine

The findings add to the clinical evidence supporting PCSK9 as a therapeutic target for significantly lowering LDL cholesterol.

Alnylam Pharmaceuticals published results from its Phase 1 clinical trial involving inclisiran in The New England Journal of Medicine. Read More »

Bristol-Myers Squibb releases interim analysis of lirilumab, Opvido trial

Patients in the trial have shown a 24 percent ORR.

Bristol-Myers Squibb and Innate Pharma have released the interim effectiveness analysis of its Phase 1/2 trial involving the lirilumab and Opdivo combination. Read More »

Crescendo to present Vectra DA at ACR meeting

These findings provide additional information for rheumatologists.

Crescendo Biosciences gave four poster presentations showcasing Vectra DA at the American College of Rheumatology meeting in Washington D.C. this week. Read More »

American Cancer Society, CVS present grants to tobacco-free schools

The tobacco-free campus grants are worth $3.6 million.

The American Cancer Society has partnered with the CVS Health Foundation to present grants to 20 institutions across the United States for their Tobacco-Free Generation Campus Initiative. Read More »

Merck receives prestigious R&D 100 Award

Merck has now received an R&D 100 Award for five consecutive years.

Merck has received the R&D 100 Award from R&D magazine. Read More »

EC approves Janssen’s STELARA

STELARA is the first biologic therapy designed to treat Crohn’s disease that actively targets the interleukin (IL)-12 and IL-23 cytokines.

Janssen-Cilag International NV's STELARA has been approved by the European Commission to treat adult patients who have moderate-to-severe Crohn’s disease and did not respond well to or are immune to conventional therapy or a tumor necrosis factor alpha antagonist. Read More »

Biothera presents new Impirme PGG data at SITC meeting

New discoveries in multiple in vivo preclinical models validate prior in vitro research.

Biothera Pharmaceuticals recently presented new Phase 2 Imprime PGG preclinical data that will corroborate the drug’s ability to produce coordinated innate and adaptive immune responses that could increase the effectiveness of other checkpoint inhibitor therapies. Read More »

Imprimis enters purchase and supply agreement with PBM